Journal
DRUG METABOLISM AND PHARMACOKINETICS
Volume 28, Issue 6, Pages 468-474Publisher
JAPANESE SOC STUDY XENOBIOTICS
DOI: 10.2133/dmpk.DMPK-12-RG-143
Keywords
carboxylesterase; antihypertensive drugs; enzyme kinetics; inhibition; microsomes; toxicology; prodrugs; drug interaction
Categories
Funding
- Hubei Natural Science Foundation of China [2011CDB550]
- National Natural Science Foundation of China [81301953]
Ask authors/readers for more resources
Human carboxylesterase (CES) 1A and CES2, two major forms of human CES, dominate the pharmacokinetics of most prodrugs such as imidapril and irinotecan (CPT-11). Antihypertensive drugs are often prescribed for clinical therapy concurrently with others. Moreover, two or more antihypertensive drugs are ubiquitously combined. The influences of antihypertensive drugs on the activity of CES remain undefined. In the present study, the inhibitory effects of 17 antihypertensive drugs on the CES1A1 and CES2 activities were evaluated. Imidapril and CPT-11 were used as substrates and cultured with liver microsomes in vitro. The imidapril hydrolase activities by recombinant CES1A1 and human liver microsomes (HLM) were intensely inhibited by telmisartan and nitrendipine (K-i = 0.49 +/- 0.09 and 1.12 +/- 0.39 mu M for CES1A1, 1.69 +/- 0.17 mu M and 1.24 +/- 0.27 mu M for HLM, respectively). However, other drugs did not exert strong inhibition. The enzyme hydrolase activity of recombinant CES2 was substantially inhibited by diltiazem and verapamil (K-i = 0.25 +/- 0.02 and 3.84 +/- 0.99 mu M, respectively). Hence, diltiazem, verapamil, nitrendipine and telmisartan may attenuate the drug efficacy of catalyzed prodrugs by changing the activities of CES1A1 and CES2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available